التفاصيل البيبلوغرافية
| العنوان: |
High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma. |
| المؤلفون: |
Dimopoulos, Meletios A., Barlogie, Bart, Smith, Terryb L., Alexanian, Raymond, Dimopoulos, M A, Barlogie, B, Smith, T L, Alexanian, R |
| المصدر: |
Annals of Internal Medicine; 12/15/91, Vol. 115 Issue 12, p931-935, 5p |
| مصطلحات موضوعية: |
MULTIPLE myeloma, LACTATE dehydrogenase, ANTINEOPLASTIC agents, COMPARATIVE studies, DRUG resistance, GENES, KARYOTYPES, RESEARCH methodology, MEDICAL cooperation, PROGNOSIS, RESEARCH, RESEARCH funding, SURVIVAL analysis (Biometry), TIME, EVALUATION research, PROPORTIONAL hazards models |
| مستخلص: |
Objective: To evaluate serum lactate dehydrogenase (LDH) as a prognostic factor in previously untreated patients with multiple myeloma.Design: Study of 391 consecutive patients with uniformly treated multiple myeloma, followed until death in 63% of patients.Setting: Tertiary, referral cancer center.Patients: A total of 391 consecutive, previously untreated, symptomatic patients with various stages of multiple myeloma.Intervention: Various chemotherapy regimens that included doxorubicin or glucocorticoids, or both, with a consistent response rate (53%).Measurements: Outcomes included clinical response based on a 75% reduction of calculated tumor load and survival time from treatment. Univariate and multivariate analyses were used.Main Results: Eleven percent of patients showed a high serum LDH level of more than 5.0 mukat/L (300 U/L). An elevated LDH level was seen more frequently with a rise in the tumor load; an increased level was present in 26% of patients with high tumor mass. A high LDH level was associated with plasma cell leukemia or lymphoma-like clinical features (43%) and with plasma cell hypodiploidy (17%). Only 20% of patients with elevated LDH levels responded to chemotherapy compared with a response rate of 57% for patients with low levels of LDH. Using multivariate analysis, LDH was a significant independent predictor of response (P = 0.001), with an odds ratio of 0.25 (95% Cl, 0.11 to 0.57). A high LDH level was associated with a short median survival (9 months) and showed the highest relative risk (2.63; Cl, 1.75 to 3.95; P = 0.001).Conclusions: Elevation of the LDH level suggests the presence of occult extraosseous disease and high tumor mass. The LDH level is a predictor of a poor prognosis in selected patients who should be considered for early intensive treatment. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Internal Medicine is the property of American College of Physicians and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
